Key Points
- Insider sale: Martin Javier San sold 1,644 shares on Jan. 2 at an average price of $6.88 for $11,310.72, reducing his position by 13.89% to 10,189 shares; the trade was disclosed in an SEC filing.
- Company performance and market view: ATHA shares were down about 5.5% (opened $6.58) after the company reported a quarterly EPS of ($1.68) that missed estimates, and analysts maintain an average "Sell" rating with a $4 target while the stock carries a market cap of roughly $25.9M.
Athira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) insider Martin Javier San sold 1,644 shares of Athira Pharma stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $6.88, for a total transaction of $11,310.72. Following the completion of the sale, the insider directly owned 10,189 shares of the company's stock, valued at approximately $70,100.32. The trade was a 13.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Athira Pharma Trading Down 5.5%
ATHA opened at $6.58 on Tuesday. The company's fifty day moving average price is $5.03 and its two-hundred day moving average price is $4.27. Athira Pharma, Inc. has a 1-year low of $2.20 and a 1-year high of $8.36. The company has a market cap of $25.93 million, a price-to-earnings ratio of -0.68 and a beta of 2.79.
Athira Pharma (NASDAQ:ATHA - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($1.51). As a group, equities analysts forecast that Athira Pharma, Inc. will post -2.35 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Athira Pharma
A hedge fund recently raised its stake in Athira Pharma stock. BML Capital Management LLC increased its holdings in shares of Athira Pharma, Inc. (NASDAQ:ATHA - Free Report) by 0.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,230,667 shares of the company's stock after acquiring an additional 30,000 shares during the quarter. Athira Pharma makes up about 0.7% of BML Capital Management LLC's holdings, making the stock its 17th largest position. BML Capital Management LLC owned about 8.27% of Athira Pharma worth $976,000 at the end of the most recent quarter. Institutional investors and hedge funds own 57.12% of the company's stock.
Analyst Upgrades and Downgrades
ATHA has been the subject of several analyst reports. Mizuho set a $4.00 price objective on Athira Pharma in a research note on Friday, September 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Athira Pharma in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of "Sell" and an average target price of $4.00.
Check Out Our Latest Research Report on ATHA
Athira Pharma Company Profile
(
Get Free Report)
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira's research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company's overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira's pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
